Robert F. Williamson III Buys 6,266 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III bought 6,266 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were purchased at an average price of $3.64 per share, with a total value of $22,808.24. Following the completion of the acquisition, the director now owns 430,058 shares of the company’s stock, valued at $1,565,411.12. This trade represents a 1.48 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $4.12 on Friday. The business has a 50-day simple moving average of $10.78 and a two-hundred day simple moving average of $12.32. Perspective Therapeutics, Inc. has a 52-week low of $2.28 and a 52-week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, equities research analysts expect that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics in the third quarter worth $57,000. US Bancorp DE boosted its stake in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after acquiring an additional 3,866 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics during the second quarter worth about $117,000. Point72 DIFC Ltd bought a new stake in Perspective Therapeutics during the 2nd quarter valued at approximately $118,000. Finally, Intech Investment Management LLC purchased a new position in Perspective Therapeutics in the 3rd quarter worth approximately $137,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. UBS Group started coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective for the company. Royal Bank of Canada cut their price objective on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Finally, Truist Financial began coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.